Recently, VT3989, a TEAD inhibitor targeting the Hippo-YAP pathway, was well tolerated and demonstrated promising antitumor activity, including partial responses, in patients with mesothelioma and NF2-mutant tumors. Here, NF2 is linked to mesothelioma.